Hortense sells RMD 49.37: Long-term Non-invasive Positive Pressure Ventilation Treatment Delivers 76 Percent Reduction in Risk of Death at One Year among ...
This is according to a new multi-center, randomized study published online in The Lancet Respiratory Medicine, and co-funded by ResMed (NYSE:RMD), the global leader in the treatment of sleep-disordered breathing and other respiratory conditions. ...
45 people liked this
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home